Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update.
Sankar D NavaneethanSophia ZoungasM Luiza CaramoriJuliana Chung Ngor ChanHiddo J Lambers HeerspinkClint HurstAdrian LiewErin Donelly MichosWasiu A OlowuTami SaduskyNikhil TandonKatherine R TuttleChristoph WannerKaty G WilkensJonathan C CraigDavid J TunnicliffeMarcello TonelliMichael CheungAmy EarleyEllen BurgessIan H de BoerKamlesh KhuntiPublished in: Annals of internal medicine (2023)
The updated guideline includes 13 recommendations and 52 practice points for clinicians caring for patients with diabetes and chronic kidney disease (CKD). A focus on preserving kidney function and maintaining well-being is recommended using a layered approach to care, starting with a foundation of lifestyle interventions, self-management, and first-line pharmacotherapy (such as sodium-glucose cotransporter-2 inhibitors) demonstrated to improve clinical outcomes. To this are added additional drugs with heart and kidney protection, such as glucagon-like peptide-1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists, and interventions to control risk factors for CKD progression and cardiovascular events, such as blood pressure, glycemia, and lipids.
Keyphrases
- chronic kidney disease
- cardiovascular events
- cardiovascular disease
- end stage renal disease
- physical activity
- blood pressure
- healthcare
- palliative care
- coronary artery disease
- quality improvement
- type diabetes
- primary care
- heart failure
- hypertensive patients
- heart rate
- clinical practice
- pain management
- reduced graphene oxide
- blood glucose
- smoking cessation
- peritoneal dialysis